Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesMerck CDR (CAD Hedged)

Merck CDR (CAD Hedged)

Healthcare Drug Manufacturers - General
PortfolioPortfolio WatchlistWatchlist
Company price
33.3 CAD 1.22 ( 3.80%)
Last update at 2026-11-04T20:41:00Z
VOLUME
12894
Market Cap
296286.70M
P/E
15.70

Momentum Score

…

Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. The company has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. It has a collaboration agreement with Antengene Corporation Limited to evaluate the combination of ATG-022, a CLDN18.2-targeting antibody-drug conjugate, and anti-PD-1 therapy, as well as KEYTRUDA (pembrolizumab) in patients with advanced solid tumors. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
32.53
Low
33.30
High
52 Week Price Range
16.37
Low
28.11
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Merck CDR (CAD Hedged) is a Toronto-listed depositary receipt for Merck & Co., a multinational pharmaceutical company that develops and commercializes prescription medicines, vaccines and animal health products. Long-term growth may be supported by its oncology and vaccine franchises, pipeline progress and global commercial scale, and the CAD-hedged structure may benefit Canadian investors by reducing currency risk.
Material risks include clinical and regulatory setbacks, patent expirations with generic competition, pricing and reimbursement pressures, and R&D execution that could weaken future revenues.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
32.08
Dividend Yield
12.32%
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
3690.70%
Net Debt
34774.00M
ROCE
19.55%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Type yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Income before tax 21067.00M 19936.00M 1889.00M 16444.00M
Net income 18254.00M 17117.00M 365.00M 14519.00M
Selling general administrative 10610.00M 10733.00M 10382.00M 9948.00M
Gross profit 52984.00M 49470.00M 44200.00M 42077.00M
Operating income 21221.00M 19912.00M 1782.50M 17945.00M
Tax provision 2804.00M 2803.00M 1512.00M 1918.00M
Interest income -663.00M 1069.00M 811.00M 2461.00M
Extraordinary items - - 0.00M 0.00M
Total revenue 65011.00M 64168.00M 60115.00M 59283.00M
Total operating expenses 43790.00M 44256.00M 58332.50M 41338.00M
Cost of revenue 12027.00M 14698.00M 15915.00M 17206.00M
Net income applicable to common shares 18254.00M 17117.00M 365.00M 14519.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Type yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total assets 136866.00M 117106.00M 106675.00M 109160.00M
Intangible assets 26681.00M 16370.00M 18011.00M 20269.00M
Other current assets 10518.00M 7865.00M 7645.00M 6509.00M
Total liab 84204.00M 70793.00M 69094.00M 63169.00M
Total stockholder equity 52606.00M 46313.00M 37581.00M 45991.00M
Common stock - 1788.00M 1788.00M 1788.00M
Capital stock 1788.00M - - -
Retained earnings 73075.00M 63069.00M 53895.00M 61081.00M
Good will 21579.00M 21668.00M 21197.00M 21204.00M
Other assets - 13544.00M 9310.00M 6752.00M
Cash 14565.00M - - -
Cash and equivalents - 13242.00M 6841.00M 12694.00M
Total current liabilities 28327.00M 28420.00M 25694.00M 24239.00M
Net debt 34774.00M - - -
Short term debt - 0.00M 0.00M 0.00M
Short long term debt 2589.00M - - -
Other stockholder equity - -4945.00M -5161.00M -4768.00M
Property plant equipment - 25149.00M 24488.00M 22768.00M
Total current assets 43516.00M 38782.00M 32168.00M 35722.00M
Long term investments 956.00M - - -
Short term investments 0.00M 447.00M 252.00M 498.00M
Net receivables 11775.00M 10278.00M 10349.00M 9450.00M
Long term debt 46750.00M 34462.00M 33683.00M 28745.00M
Inventory 6658.00M 6109.00M 6358.00M 5911.00M
Accounts payable 4404.00M - - -
Non currrent assets other 18818.00M - - -
Non current assets total 93350.00M - - -
Long term debt total - 34462.00M 33683.00M 28745.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Type yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Investments 471.00M - - -
Total cashflows from investing activities - -7734.00M -14083.00M -4960.00M
Net borrowings 11377.00M - - -
Total cash from financing activities -1922.00M -7032.00M -4810.00M -9119.00M
Net income 18254.00M 17133.00M 377.00M 14526.00M
Change in cash 1372.00M 6409.00M -5864.00M 4606.00M
Begin period cash flow 13318.00M - - -
End period cash flow 14690.00M - - -
Total cash from operating activities 16472.00M 21468.00M 13006.00M 19095.00M
Depreciation 5838.00M 2104.00M 1828.00M 1824.00M
Other cashflows from investing activities - -4362.00M -10220.00M -572.00M
Dividends paid -8176.00M 7840.00M 7445.00M 7012.00M
Change to inventory -1180.00M - - -
Change to account receivables -1090.00M - - -
Sale purchase of stock -5084.00M -1129.00M -1221.00M 384.00M
Other cashflows from financing activities - -372.00M -328.00M -240.00M
Capital expenditures 4112.00M 3372.00M 3863.00M 4388.00M
Change in working capital -6976.00M -3667.00M -2205.00M -2782.00M
Stock based compensation 820.00M - - -
Other non cash items 511.00M - - -
Free cash flow 12360.00M - - -

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - General

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
MRK
Merck CDR (CAD Hedged)		 1.22
3.80%		 33.30 15.70 22.32 4.40 5.36 4.81 11.07
NOVO
Novo Nordisk CDR (CAD Hedged)		 0.92
5.27%		 18.37 3.31 3.54 1.10 1.74 3.88 7.66
AMGN
Amgen CDR (CAD Hedged)		 1.29
3.78%		 35.38 24.19 15.65 5.06 21.36 6.30 13.69
GILD
Gilead Sciences CDR (CAD Hedged)		 1.30
3.84%		 35.12 19.51 15.04 5.62 7.21 6.14 13.31
SNY
Sanofi CDR (CAD Hedged)		 0.60
2.84%		 21.74 3.25 1.53 0.34 0.22 2.33 8.73

Profile*

Merck CDR (CAD Hedged)

Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. The company has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. It has a collaboration agreement with Antengene Corporation Limited to evaluate the combination of ATG-022, a CLDN18.2-targeting antibody-drug conjugate, and anti-PD-1 therapy, as well as KEYTRUDA (pembrolizumab) in patients with advanced solid tumors. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

126 East Lincoln Avenue, Rahway, NJ, United States, 07065

908 740 4000

https://www.merck.com

73000

Name Title Year Born
Mr. Robert M. Davis J.D. Chairman, President & CEO 1967
Ms. Caroline A. Litchfield Executive VP & CFO 1969
Ms. Betty D. Larson Executive VP & Chief Human Resources Officer 1976
Mr. Richard R. DeLuca Jr. Executive VP & President of Merck Animal Health 1963
Dr. Dean Y. Li M.D., Ph.D. Executive VP & President of Merck Research Laboratories 1963
Mr. Dalton E. Smart III Senior VP of Finance, Principal Accounting Officer & Global Controller 1967
Mr. David Michael Williams Executive VP and Chief Information & Digital Officer 1969
Mr. Peter Dannenbaum Vice President of Investor Relations NA
Ms. Jennifer L. Zachary J.D. Executive VP & General Counsel 1978
Mr. Sanat Chattopadhyay Executive VP & President of Merck Manufacturing Division 1960

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.50
+15.05%
DSV
CAD 11.02
+14.55%
USA
CAD 4.29
+13.19%
NUAG
CAD 7.70
+12.90%
GMIN
CAD 43.79
+12.86%
DRUG
CAD 26.11
-29.58%
HUT
CAD 68.98
-22.41%
UCU
CAD 2.09
-14.34%
VET
CAD 14.87
-14.29%
PHX
CAD 10.96
-13.56%

Equity Sectors*

  • Basic Materials

    +5.46%

  • Communication Services

    +3.38%

  • Consumer Cyclical

    +3.11%

  • Consumer Defensive

    +1.35%

  • Energy

    -4.79%

  • Financial Services

    +2.66%

  • Healthcare

    -0.72%

  • Industrials

    -0.11%

  • Real Estate

    +1.84%

  • Technology

    +1.05%

  • Utilities

    +0.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…